Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres

Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinoma MARLBOROUGH, Mass., March 18, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) announced it has receiv... Devices, Oncology, FDA Boston Scientific, TheraSphere, Y-90, Glass Microspheres, radioembolization

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2046735

Source: HSMN NewsFeed - March 18, 2021 Category: Pharmaceuticals Source Type: news